Labcorp Oncology offers a comprehensive test menu to support you in the diagnosis and treatment of patients with ovarian cancer throughout their continuum of care.
Genetic Risk Assessment
BRCAssure® BRCA1/2 Analysis
- Mutations in BRCA1 and BRCA2 account for the vast majority of families with hereditary breast and ovarian cancer syndrome (HBOC).1
- The estimated lifetime risk for breast and ovarian cancer is significantly increased in women with BRCA1/2 mutations.1
VistaSeq® Hereditary Cancer Panels
- Provide an assessment of genetic mutations known to be associated with hereditary cancer syndromes. Available panels include:
- Hereditary Cancer Panel
- Hereditary Cancer Panel minus BRCA1/2 genes
- GYN Cancer Panel
- Breast Cancer Panel
- Breast and GYN Cancer Panel
- Genetic tests, like VistaSeq and BRCAssure, inform a patient's risk of cancer and may guide therapy for patients with cancer.
- Mutation-specific sequencing for patients with a family history of known germline mutations is also available.
Complex Tumor Analysis by IHC
Our extensive antibody library and team of pathologists can provide a differential diagnostic analysis in even the most complex cases.
CDX2/CK7 by IHC – useful to distinguish stomach and colon carcinoma from ovarian carcinoma.
p53 by IHC
Abnormal expression of p53 can help distinguish between low grade and high grade serous ovarian carcinomas.
Ovarian Malignancy Risk (ROMA®)
The ROMA® (Risk of Ovarian Malignancy Algorithm) calculation combines the results of the Roche Elecsys HE4 assay, Elecsys CA 125 II assay and menopausal status into a numerical score.
The ROMA value is intended to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian mass is at high or low likelihood of finding malignancy at the time of surgery.
BRAF Gene Mutation Analysis
This test will detect all V600 mutations of the BRAF oncogene frequently found in human cancers, including ovarian cancer, allowing the determination of drug response, aiding the diagnosis and providing prognosis information.
BRAF mutation is associated with early-stage disease and Improved outcomes in patients with low-grade serous ovarian cancer.2
Biomarkers for Therapeutic Selection
Biomarkers and tests for clinical management and treatment decision-making
|FOLR1 by IHC |
|Folate Receptor 1 protein (FOLR1 or FRɑ) expression||Mirvetuximab soravtansine-gynx for patients with platinum-resistant ovarian cancer 3|
|ER by IHC |
PR by IHC
|ER/PR protein expression||Hormonal therapies|
|BRAF Gene Mutation Analysis||Mutations in the BRAF gene (e.g., V600E)||BRAF inhibitor|
|Microsatellite Instability (MSI) or Mismatch Repair (MMR) Proteins by IHC||Microsatellite instability (MSI)/ mismatch repair (MMR) deficiency||Pembrolizumab4, dostarlimab-gxly5|
|OmniSeq INSIGHT®, Solid Tumor NGS Panel (DNA and RNA)||Includes DNA and RNA sequencing (523 genes), MSI, TMB*, fusion analysis including NTRK and RET, PD-L1 IHC and immune gene profiling||Targeted therapies and immunotherapies|
|BRCAssure® BRCA1/2Analysis||BRCA1 and BRCA2 gene mutations||PARP inhibitor|
|VistaSeq® Hereditary Cancer Panels||BRCA1, BRCA2, and other hereditary cancer gene mutations||PARP inhibitor|
*TMB - tumor mutational burden
Ovarian cancer specific blood-based tumor markers
Primarily for epithelial ovarian cancer
For mucinous ovarian cancer
Inhibin A and B
For granulosa cell ovarian cancers
Human epididymis protein 4 (HE4)
For epithelial ovarian cancers
For germ cell ovarian cancers
Human chorionic gonadotropin (hCG, β-subunit)
For germ cell ovarian cancers
- Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [updated 2022 May 26]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. PMID: 20301425.
- Grisham RN, Iyer G, Garg K, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013 Feb 1;119(3):548-554. doi: 10.1002/cncr.27782. Epub 2012 Aug 28. PMID: 22930283; PMCID: PMC3961140.
- ELAHERE® (mirvetuximab soravtansine-gynx) [package insert]. ImmunoGen, Inc., MA; 2022.
- KEYTRUDA® (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck &Co., Inc.; 2021.
- JEMPERLI (dostarlimab-gxly) [package insert]. Philadelphia, PA: GlaxoSmithKline LLC; 2023.